Immatics US
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Immatics US sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Immatics US: 7 sponsored US clinical trials, 3 recruiting.
Immatics US sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Cancer, with 2 trials.
Upper-quartile sponsor footprint
Immatics US sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124
TCR-engineered T Cells in Solid Tumors: IMA202-101
NCT03441100
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
NCT03760952
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
NCT03247309
ACTolog in Patients With Solid Cancers
NCT02876510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Immatics US pipeline
3 recruiting of 7 indexed (43% open); 4 completed (57%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Recurrent Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Immatics US: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
Immatics US sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this Immatics US page
7 registered trials is a research-attention snapshot, not an endorsement of Immatics US or any single study.
- 3 of Immatics US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Recurrent Cancer is the condition Immatics US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Immatics US pipeline card: 7 registered trials from official public datasets.Report a data error.